Phathom Pharmaceuticals Presents 31 Vonoprazan Abstracts at DDW 2026 Across Key GI Indications

With 28 independent investigator-initiated abstracts now on record, Phathom Pharmaceuticals' vonoprazan is accumulating a clinical evidence base that formulation scientists and regulatory affairs leads should be tracking closely as the potassium-competitive acid blocker (PCAB) class moves toward broader displacement of proton pump inhibitors in acid-related disease management.

At Digestive Disease Week (DDW) 2026, held May 2–5 in Chicago, a total of 31 vonoprazan-related abstracts were presented. Three were Phathom-sponsored, including a Phase 3 pHalcon-NERD-301 analysis of heartburn and regurgitation endpoints measured via the validated PAGI-SYM instrument, which DDW recognised as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. The remaining 28 abstracts were independent, investigator-initiated studies from academic and clinical researchers across the United States, Europe, Asia, and South America.

The independent data covered a range of clinically and operationally relevant areas. A network meta-analysis drawing on 77 randomised controlled trials evaluated vonoprazan-based H. pylori eradication regimens. Separate propensity-matched cohort analyses examined long-term safety signals, specifically rates of vitamin B12 deficiency, hypomagnesemia, and Clostridioides difficile infection, when comparing vonoprazan against traditional PPIs. Two systematic reviews assessed delayed post-procedural bleeding following endoscopic submucosal dissection. Real-world data also addressed vonoprazan use in PPI-refractory GERD patients following laparoscopic sleeve gastrectomy, a population where standard acid suppression protocols frequently require reassessment.

For drug development and CMC teams, the expanding PCAB evidence base carries process implications. Vonoprazan's distinct mechanism, reversible, potassium-competitive binding at the H+/K+-ATPase pump, differs materially from irreversible PPI covalent binding, and those pharmacodynamic differences inform stability profiling, formulation pH sensitivity, and the design of dissolution specifications under ICH Q8 and ICH Q6A frameworks. As independent researchers extend vonoprazan into new patient subpopulations, including elderly patients and those with comorbid psychiatric conditions, the label's scope and associated post-market commitments are likely to evolve, with corresponding implications for lifecycle management filings.

The pHalcon-NERD-301 dataset, now generating multiple post hoc analyses, will serve as a reference point for any future supplemental NDA activity or label expansion discussions with FDA under 21 CFR Part 314.

Source: Phathom Pharmaceuticals via GlobeNewswire, 20 May 2026.